The current proposal takes a new direction of including immune checkpoint inhibition (ICI) therapy within the existing P01 theme of Photodynamic Therapy (PDT)-based combinations guided by molecular mechanisms and imaging. The renewal application has been revised and each of the critique comments have been addressed under introduction section and elaborated further under research strategy section. Infact, the theme is photodynamic priming (PDP) of tumors to make them immune sensitive. This priming enables tumors that were silent to immune checkpoint inhibitors (ICI) sensitive at lower concentrations with increased efficiency and tolerability. The P01 has a range of skills and geographical locations and the Administrative Core is essential to ensure an integrated conduct, facile exchange of information and a coordinated use of resources for the maximal utilization of institutional and NCI-supported resources. The budgets are very limited (average ~$150/year, ~ 50% of an average R01) and therefore the Core and its efforts at coordination of multiple sites, quality control and project data become critical. An aspiration of the Program is to create an ethos for maximal integration of the components to better serve this P01, the field of PDT, cancer research, training of the next generation, clinical translation and the community at large. To this end, the PIs have brought together a team of new and existing scientists and physicians who already collaborate enthusiastically. The Core also takes a leadership role in mid-course correction as became necessary with clinical pancreatic cancer project in the last cycle. In addition to the two broad functions of Scientific and Administrative coordination, the renewal application retains the goals of career development, intellectual property (IP) development, and data sharing for this Core. The scientific coordination will be maintained through a variety of mechanisms that will include regular intra- and inter-Project/Scientific Core meetings (Zoom or in person). This Core will: a) perform monthly reviews and identify obstacles; b) coordinate meetings with selected collaborators and key personnel; c) organize and follow up on action plans; d) organize annual SAB meeting and core/project specific discussions; e) As resources permit, achieve scientific enhancement by inviting speakers with larger perspectives on cancer therapeutics relevant to the Program, but not directly in PDT. Technologies will get IP protection where appropriate using institutional resources and find development partners consistent with one of the goals of the NIH Roadmap. In response to the reviewers’ critiques, a succession plan and a Scientific Advisory Board (SAB)is added instead of the Scientific Advisory Group. The Core was viewed as successful in the past cycle. Specially noted strengths were career development efforts, numerous joint publications and leadership. The aims were appreciated for clarity, construction and for promoting b...